ERIC CHEUNG: Open Payments
NPI 1013421973 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,247 in 92 payments from 17 companies in 2025. Trend: 2023 $2,318 · 2024 $2,131 · 2025 $2,247
Food & beverage: $2,247
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 27 | $497 |
| Phathom Pharmaceuticals, Inc. | 7 | $376 |
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $262 |
| Gilead Sciences, Inc. | 5 | $208 |
| GlaxoSmithKline, LLC. | 10 | $181 |
| Aimmune Therapeutics, Inc. | 5 | $132 |
| Novo Nordisk Inc | 5 | $101 |
| IBSA Pharma Inc. | 5 | $95 |
| Ardelyx, Inc. | 3 | $80 |
| ABBVIE INC. | 3 | $58 |
Products named: VOQUEZNA, Kerendia, OTEZLA, EVENITY, TRELEGY ELLIPTA, ZENPEP, Ozempic, Tirosint.
Industry payments across CA — which companies pay providers there.
